We offer tailored partnerships to support and transform drug discovery.
Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.
MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.
As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.
Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.
We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.
Get inspired by research done by our scientists, partners, and customers around the globe.
The trust placed in us by top global pharmaceutical and biotech players is a testament to the exceptional quality and value we deliver. With unwavering expertise and dedication, we continuously strive to provide you with outstanding results while staying at the forefront of scientific advancements.
In the rapidly evolving field of disease modeling, expertise is vital. That's why we have curated a comprehensive range of expertise under one roof at MIMETAS. Our team combines crucial biological knowledge, efficient supply chain management, cutting-edge hardware capabilities, and advanced data interpretation techniques to meet your unique requirements. Our specialities include:
Roche Partnership
In July 2021, MIMETAS and Roche entered a risk-sharing collaboration to develop human disease models for the characterization of novel compounds in Inflammatory Bowel Disease (IBD) and Hepatitis B virus infections (HBV). Under the terms of the agreement, MIMETAS is eligible to receive an upfront payment and milestone payments from Roche. You can find the original press release here. We are delighted to share that the partnership is going well and recently achieved important milestones in the project.
Astellas Pharma Inc. Partnership
In March 2023, MIMETAS and Astellas Pharma Inc. entered a strategic partnership. The partnership, which was then expanded in June 2023 to include automation and support, comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies. Under this collaboration, Astellas will receive access to MIMETAS immune oncological disease assays. MIMETAS will be eligible for upfront and milestone payments.
Learn more about Drug Discovery
The satisfaction and loyalty of our customers drive our success at MIMETAS. With unwavering expertise and dedication, we continuously strive to provide you with outstanding results while staying at the forefront of scientific advancements. Read some success stories from our customers:
Marking 10 years of impactful science, we're dedicated to further leveraging our 3D tissue expertise to provide tailored answers to your unique research questions.We foster effective collaborations, long-term relationships, and tangible impact on your therapeutic programs. We strongly value your success and plan carefully to ensure that we address your specific research questions in full. Please reach out if you would like to work together.
